Cardiovascular safety of sulphonylureas: Over 40years of continuous controversy without an answer

Diabetes, Obesity and Metabolism

Volumn 17, Issue 6, 2015, Pages 523-

  Abdelmoneim, A S ^a   Eurich, D T ^a   Light, P E ^a   Senior, P A ^a   Seubert, J M ^a   Makowsky, M J ^a   Simpson, S H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiovascular disease; Sulphonylureas

Indexed keywords

PROINSULIN; SULFONYLUREA; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ANTIDIABETIC ACTIVITY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DRUG SAFETY; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SELECTION BIAS; WEIGHT GAIN; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DIABETES MELLITUS;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; SULFONYLUREA COMPOUNDS;

EID: 84928429195     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12456     Document Type: Review

References (103)

1. Thulé PM, Umpierrez G. Sulfonylureas: a new look at old therapy. Curr Diab Rep 2014; 14: 473.
2. Pitocco D, Valle D, Rossi A, Gentilella R. Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents. J Endocrinol Invest 2008; 31: 371-379.
3. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee of the Canadian Diabetes Advisory Board. Canadian Diabetes Association 2013 Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2013, 37(Supp 1):S1-S212.
4. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
5. Abdelmoneim A, Eurich DT, Gamble J, Simpson SH. Use patterns of antidiabetic regimens by patients with type 2 diabetes. Can J Diabetes 2013; 37: 394-400.
6. Cohen FJ1, Neslusan CA, Conklin JE et al. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 2003; 26: 1847-1851.
7. Boyc KS, Yurgin N, Lage MJ. Trends in the prescription of antidiabetic medications in France: evidence from primary care physicians. Adv Ther 2007; 24: 803-813.
8. Filion KB, Joseph L, Boivin JF et al. Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf 2009; 18: 973-976.
9. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19(Suppl.): 789-830.
10. Bell DSH. Do sulfonylurea drugs increase the risk of cardiac events ? Can Med Assoc J 2006; 174: 185-186.
11. Pantalone KM. Dose mortality risk vary among sulfonylureas? Lancet Diabetes Endocrinol 2015; 3: 6-7.
12. Nissen SE. Cardiovascular effects of diabetes drugs: emerging from the dark ages. Ann Intern Med 2012; 157: 671-672.
13. Rosenstock J, Marx N, Kahn SE etal. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013; 10: 289-301.
14. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972; 21: 976-979.
15. Schwartz TB, Meinert CL. The UGDP controversy: thirty-four years of contentious ambiguity laid to rest. Perspect Biol Med 2004; 47: 564-574.
16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
17. Ohneda A, Maruhama Y, Itabashi H etal. Vascular complications and long-term administration of oral hypoglycemic agents in patients with diabetes mellitus. Tohoku J Exp Med 1978; 124: 205-222.
18. Halkin A, Roth A, Jonas M etal. Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 2001; 12: 177-184.
19. Jollis JG, Simpson RJ Jr, Cascio WE etal. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 1999; 138: S376-380.
20. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
21. Kassem SA, Raz I. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. Diabetes Care 2009; 32 (Suppl. 2): S337-341.
22. Bianchi C, Miccoli R, Daniele G etal. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes Care 2009; 32(Suppl. 2): S342-348.
23. Pantalone M, Kattan MW, Yu C etal. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analyis. Diabetes Obesity and Metabolism 2012; 14: 803-809.
24. Evans JMM, Ogston SA, Emslie-Smith A etal. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-936.
25. Corrao G, Romio SA, Zambon A etal. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy. Eur J Clin Pharmacol 2011; 67: 289-299.
26. Roumie C, Hung AM, Greevy RA etal. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus. Ann Intern Med 2012; 157: 601-610.
27. Danchin N, Charpentier G, Ledru F etal. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev 2005; 21: 143-149.
28. Horsdal HT, Johnsen SP, Søndergaard F etal. Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study. Diabetologia 2008; 51: 567-574.
29. Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med 2013; 30: 1160-1171.
30. Forst T, Hanefeld M, Jacob S etal. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res 2013; 10: 302-314.
31. Hemmingsen B, Schroll JB, Lund SS etal. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus (review). 2013; 4: CD009008.
32. Rao AD, Kuhadiya N, Reynolds K etal. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all- cause mortality? Diabetes Care 2008; 31: 1672-1678.
33. Selvin E, Bolen S, Yeh HC etal. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070-2080.
34. Zhang Y, Hong J, Chi J etal. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 2014; 30: 241-256.
35. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; 15: 938-953.
36. Simpson S, Lee J, Choi S etal. Mortality risk varies amongst sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 2014; 3: 43-51.
37. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892.
38. Hong J, Zhang Y, Lai S etal. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013; 36: 1304-1311.
39. Vaccaro O, Masulli M, Bonora E et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutrition Metabolism and Cardiovascular Diseases 2012; 22: 997-1006.
40. UKPDS Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991; 34: 877-890.
41. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
42. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
43. Duckworth W, Abraira C, Moritz T etal. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
44. Sasali A, Leahy JL. Is metformin cardioprotective? Diabetes Care 2003; 26: 243-244.
45. Saenz A, Fernandez-Esteban I, Mataix A, etal. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 3: CD002966.
46. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
47. Holman RR, Paul SK, Bethel MA etal. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
48. Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013; 39: 179-190.
49. Lexis CPH, van der Horst ICC, Lipsic E, etal. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes. JAMA 2014; 311:1526-1535.
50. Patorno E, Patrick AR, Garry EM etal. Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations. Diabetologia 2014; 57: 2237-2250.
51. Rothman KJ, Greenland S, Lash T. Modern Epidemiology. Philadelphia: Lippincot Williams & Wilkins, 2008.
52. Byrd JB, Ho PM. The possibility of unmeasured confounding variables in observational studies: a forgotten fact? Heart 2011; 97: 1815-1816.
53. Stürmer T, Rothman KJ, Avorn J etal. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution-a simulation study. Am J Epidemiol 2010; 172: 843-854.
54. Schneeweiss S, Rassen JA, Glynn RJ etal. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20: 512-522.
55. Brookhart M, Rassen J, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf 2010; 19: 537-554.
56. Harpe SE. Using secondary data sources for pharmacoepidemiology and outcomes research. Pharmacotherapy 2009; 29: 138-153.
57. Hak E, Verheij TJM, Grobbee DE etal. Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. Epidemiol Community Health 2002; 56: 951-955.
58. Lobo FS, Wagner S, Gross CR etal. Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res Social Adm Pharm 2006; 2: 143-151.
59. Sullivan D, Forder P, Simes J etal. Associations between the use of metformin, sulphonylureas, or dietalone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. Diabetes Res Clin Pract 2011; 94: 284-290.
60. Andersson C, Olesen JB, Hansen PR etal. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 2010; 53: 2546-2553.
61. Kahler KH, Rajan M, Rhoads GG, et al. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care 2007; 30: 1689-1693.
62. Schramm TK, Gislason GH, Vaag A et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationawid study. Eur Heart J 2011; 32: 1900-1908.
63. Monami M, Dicembrini I, Kundisova L, Zannoni S, Nreu B, Mannucci E. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes Obes Metab 2014; 16: 833-840.
64. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
65. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol 1989; 54: 87-143.
66. Nichols CG, Singh GK, Grange DK. KATP channels and cardiovascular disease: suddenly a syndrome. Circ Res 2013; 112: 1059-1072.
67. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997; 77: 1165-1232.
68. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
69. Bolli R. Preconditioning : a paradigm shift in the biology of myocardial ischemia. Am J Physiol Heart Circ Physiol 2007; 292: H19-27.
70. Hausenloy DJ, Candilio L, Laing C etal. Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial. Clin Res Cardiol 2012; 101: 339-348.
71. Suzuki M, Sasaki N, Miki T etal. Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest 2002; 109: 509-516.
72. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992; 70: 223-233.
73. Samaha FF, Heineman FW, Ince C etal. ATP-sensitive potassium channel is essential to maintain basal coronary vascular tone in vivo. Am J Physiol 1992; 262: C1220-1227.
74. Imamura Y, Tomoike H, Narishige T etal. Glibenclamide decreases basal coronary blood flow in anesthetized dogs. Am J Physiol 1992; 263: H399-404.
75. Cole WC, McPherson CD, Sontag D. ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991; 69: 571-581.
76. Toombs CF, Moore TL, Shebuski RJ. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res 1993; 27: 617-622.
77. Mitani A, Kinoshita K, Fukamachi K etal. Effects of glibenclamide and nicorandil on cardiac function during ischemia and reperfusion in isolated perfused rat hearts. Am J Physiol 1991; 261: H1864-1871.
78. Schulz R, Rose J, Heusch G. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine. Am J Physiol 1994; 267: H1341-1352.
79. Tomai F, Crea F, Gaspardone A etal. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90: 700-705.
80. Cleveland JC, Meldrum DR, Cain BS etal. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 1997; 96: 29-32.
81. Abdelmoneim S, Hasenbank SE, Seubert JM etal. Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab 2012; 14: 130-138.
82. Klepzig H, Kober G, Matter C etal. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439-446.
83. Kristiansen SB, Løfgren B, Nielsen JM etal. Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes. Diabetologia 2011; 54: 451-458.
84. Gangji AS, Cukierman T, Gerstein HC etal. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30: 389-394.
85. Moheet A, Seaquist ER. Hypoglycemia as a driver of cardiovascular risk in diabetes. Curr Atheroscler Rep 2013; 15: 351.
86. Desouza C, Salazar H, Cheong B etal. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003; 26: 1485-1489.
87. The ORIGIN Trial Investigators. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013; 34: 3137-3144.
88. Landstedt-Hallin L, Englund A, Adamson U, et al. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med 1999; 246: 299-307.
89. Wang J, Alexanian A, Ying R etal. Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase. Arterioscler Thromb Vasc Biol 2012; 32: 712-720.
90. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 2008; 24: 353-363.
91. Schopman JE, Simon AC, Hoefnagel SJ etal. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev 2014; 30: 11-22.
92. Korhonen MJ, Huupponen R, Ruokoniemi P etal. Protopathic bias in observational studies on statin effectiveness. Eur J Clin Pharmacol 2009; 65: 1167-1168.
93. Stricker BHC, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 2010; 25: 245-251.
94. Pantalone KM, Kattan MW, Yu C etal. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy. Diabetes Care 2010; 33: 1224-1229.
95. Zeller M, Danchin N, Simon D etal. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010; 95: 4993-5002.
96. Khalangot M, Tronko M, Kravchenko V etal. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 2009; 86: 247-253.
97. Mogensen UM, Andersson C, Fosbøl EL etal. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus - a retrospective nationwide study. Diabetes Obes Metab 2014; 16: 1001-1008.
98. Garratt KN, Brady PA, Hassinger NL etal. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119-124.
99. Riveline J, Danchin N, Ledru F etal. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003; 29: 207-222.
100. Meier JJ, Gallwitz B, Schmidt WE etal. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004; 90: 9-12.
101. Simpson SH, Majumdar SR, Tsuyuki RT etal. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. Can Med Assoc J 2006, 174: 169-174.
102. Abdelmoneim A, Eurich DT, Gamble JM etal. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study. Diabetes Obes Metab 2013; 16: 22-9.
103. Riddle MC. More reasons to say goodbye to glyburide. J Clin Endocrinol Metab 2010; 95: 4867-4870.